Nefopam


Generic Medicine Info
Administration
May be taken with or without food. May be taken w/ meals if GI discomfort occurs.
Contraindications
History of convulsive disorders. IM/IV: Urinary retention linked to urinary or prostate disorders, angle-closure glaucoma. Oral: Concomitant use with MAOIs.
Special Precautions
Patient with angle-closure glaucoma, urinary retention, benign prostatic hyperplasia, CV disease or history of ischaemic heart disease. Patient concomitantly taking TCA. Not recommended for the treatment of MI. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. IM/IV: Not indicated for the treatment of chronic pain; not advisable for use in the elderly. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal and hepatic function; signs of anticholinergic effects (e.g. nausea, sweating) particularly within approx 15 minutes of administration (IM/IV).
Adverse Reactions
Significant: Anticholinergic effects (e.g. blurred vision, xerostomia, constipation, urinary retention), sympathomimetic effects (e.g. tachycardia, exacerbation of angina); drug dependence and abuse. Rarely, transient pink discolouration of urine. Cardiac disorders: Palpitations. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain. Immune system disorders: Angioedema, allergic reactions. Nervous system disorders: Dizziness, drowsiness, headache, paraesthesia, tremor, convulsion, lightheadedness. Psychiatric disorders: Insomnia, nervousness, confusion, hallucination. Skin and subcutaneous tissue disorders: Diaphoresis. Vascular disorders: Hypotension, syncope.
Drug Interactions
May cause serotonin toxicity (including serotonin syndrome) with TCAs and SSRIs. May result in additive adverse effects with other anticholinergic or sympathomimetic agents.
ATC Classification
N02BG06 - nefopam ; Belongs to the class of other analgesics and antipyretics.
Disclaimer: This information is independently developed by CIMS based on nefopam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in